ArticlePloS one2025
Global trends in smoking-attributable rheumatoid arthritis burden: Insights from GBD 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmoking is one of the most significant environmental risk factors for Rheumatoid Arthritis (RA). However, there is a lack of research examining the impact of smoking trends on the RA disease burden globally.
methodsThis study utilized the Global Burden of Disease (GBD) 2021 database to analyze the burden of RA attributable to smoking. Five key indicators were examined: Deaths, Disability-Adjusted Life Years (DALYs), Years Lived with Disability (YLDs), Years of Life Lost (YLLs), and the Socio-Demographic Index (SDI). The analysis was stratified by age, sex, year, and region. Additionally, smoking prevalence and tobacco use data from 2000 to 2021 were extracted from the World Health Organization (WHO) to evaluate trends in smoking and RA burden.
resultsFrom 1990 to 2021, while the age-standardized Smoking Attributable Fraction for RA burden metrics generally declined globally, alongside decreasing age-standardized rates (ASR) of smoking-attributable burden in many regions, the absolute global number of both deaths and DALYs due to smoking-attributable RA paradoxically increased (deaths: from 1,792-2,264; DALYs: from 145,727-215,780; all 95% Uncertainty Intervals provided in text). Significant disparities were observed: high-income regions demonstrated greater reductions in smoking-attributable burden than low- and middle-income regions. Males and older populations experienced higher burdens across all metrics. Moderate SDI countries had the highest smoking-attributable age-standardized Deaths and YLLs rate (e.g., Deaths 0.04 per 100,000 population), whereas high SDI countries showed higher YLDs rate (e.g., 3.5 per 100,000 population).
conclusionsThis study highlights the persistent impact of smoking on the global RA burden and underscores the critical role of tobacco control policies in alleviating this burden. Tailored interventions for high-burden regions (e.g., Eastern Europe and East Asia) and high-risk populations (e.g., middle-aged and older males) are essential. Strengthening early interventions and resource allocation in low- and middle-income regions and enhancing long-term RA management in high-income regions are crucial steps to further reduce the global RA burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.